Pharmaceuticals News and Research

RSS

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents, will continue to be available for patients through Noven.

11 Aug 2010

Dicerna announces closing of $25 million Series B round of financing

Dicerna Pharmaceuticals, Inc., a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA molecules, today announced that it has closed a $25 million Series B round of financing. New investor Domain Associates led the round, with all existing investors participating - Oxford Bioscience Partners, Skyline Ventures and Abingworth.

11 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch

Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced study initiation and dosing of the first patient in the Company's pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. AG200-15 is designed to effectively deliver a low dose of estrogen in combination with levonorgestrel. The patch is applied once weekly for three weeks followed by a patch-free week.

11 Aug 2010

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended June 30, 2010.

11 Aug 2010

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office has allowed claims in a patent application (US Serial No. 12/550,579) derived from the "Tuschl III" patent series. The allowed claims relate to human microRNA miR-155, a microRNA that is a potential target for immuno-inflammatory indications, and a lead program of the Regulus-GSK Strategic Alliance.

11 Aug 2010

Cramer selects Neolane to support marketing communication programs for clients in healthcare practice

Enterprise marketing software provider Neolane, Inc. today announced that it has been selected by digital marketing and events solution company Cramer to support more effective marketing communications programs for its clients, specifically in its healthcare practice. The first program to benefit from Neolane's comprehensive, flexible marketing automation platform is a Cramer biopharmaceutical client that was seeking to improve the results of an on-going patient communications program that relies on targeted, personalized communications across multiple channels to support patient therapy.

11 Aug 2010

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

PregLem, the Swiss specialty biopharmaceutical company focused on women's reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

11 Aug 2010

Medicago USA awarded $21M to develop vaccine facility in Research Triangle Park

Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has been awarded a $21 Million grant from the Defense Advanced Research Projects Agency, Broad Agency Announcement, Defense Sciences Research & Technology to demonstrate the scalable manufacturing of its plant-expressed VLP vaccines in the U.S.A. under a Technology Investment Agreement.

11 Aug 2010

Silence Therapeutics receives patent for RNA silencing method

Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.

11 Aug 2010

Sanofi-aventis, Scripps Genomic Medicine collaborate to advance research in individualized medicine

Sanofi-aventis and Scripps Genomic Medicine, a division of Scripps Health, announced today a strategic alliance to advance research and development initiatives in the field of individualized medicine.

11 Aug 2010

NKTreg white blood cells migrate into liver, suppress immune responses: Research

After a transplant - and to assure that the new organ is not rejected - patients are put on life-long therapy to suppress their immune system, which, nevertheless, needs to be left intact enough to be able to defend the body against all kinds of disease. A tricky balance as the many rejected organs attest. But a discovery by Maria Monteiro and Luis Graça, two Portuguese scientists, could change all this, at least for the liver.

11 Aug 2010

Entelos receives patent for PhysioLab virtual patient technology

Entelos, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,774,182, entitled "Apparatus and Method for Validating a Computer Model." This patent was issued to Entelos for its invention of an innovative computer-implemented method for validating multiple virtual patients within a computer model. The PhysioLab virtual patient technology allows Entelos life scientists and engineers to more rapidly evaluate the safety and efficacy of new therapeutics in a diverse population of patients. This predictive power is integrated into our PhysioLab platforms, which have been used by our pharmaceutical and consumer product customers for over a decade to dramatically reduce the risk, time, and cost of product development.

11 Aug 2010

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Michelle Hastings, PhD, Assistant Professor in the Department of Cell Biology and Anatomy, in the Chicago Medical School of Rosalind Franklin University of Medicine and Science, has been awarded a five-year $1.68 million grant from the National Institutes of Health to support her research aimed at investigating treatments for the fatal children's disease, Spinal Muscular Atrophy (SMA).

11 Aug 2010

Immunomedics receives additional patent for CD74 target

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.

11 Aug 2010

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, announced today that it received a Notice of Allowance by the Japanese Patent Office stating a favourable decision for the patent application 2000-547262 developed at the Max-Planck Institute for Molecular Genetics in Berlin, Germany. This patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology and is already granted in Europe with the publication number EP1073770 B1.

11 Aug 2010

Sinobiopharma inks agreement with Lianhuan to co-develop, manufacture and commercialize Eplerenone

Sinobiopharma, Inc., an innovative biopharmaceutical products company with primary operations in China, today announced that the Company, through its wholly-owned subsidiary Dong Ying Pharmaceutical Co., Ltd., has signed an agreement with Jiangsu Lianhuan Pharmaceuticals Co., Ltd. to co-develop, manufacture and commercialize Eplerenone, a therapeutic agent formulated to treat high blood pressure and vascular diseases.

11 Aug 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

Omnicell announces co-marketing partnership agreement for Sentinel RCM application

Omnicell, Inc., a leading provider of system solutions to acute healthcare facilities, today announced a partnership agreement to co-market Sentry Data Systems' Sentinel RCM™ application, which has a sophisticated 340B solution component. Sentry specializes in providing solutions to address a variety of financial challenges found within hospitals and pharmacies while Omnicell's WorkflowRx™ software offers a complete inventory management system for hospital pharmacies.

From Omnicell, Inc. 11 Aug 2010

Pharmaceuticals News and Research

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Dicerna announces closing of $25 million Series B round of financing

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Cramer selects Neolane to support marketing communication programs for clients in healthcare practice

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

Medicago USA awarded $21M to develop vaccine facility in Research Triangle Park

Silence Therapeutics receives patent for RNA silencing method

Sanofi-aventis, Scripps Genomic Medicine collaborate to advance research in individualized medicine

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Entelos receives patent for PhysioLab virtual patient technology

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Immunomedics receives additional patent for CD74 target

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Sinobiopharma inks agreement with Lianhuan to co-develop, manufacture and commercialize Eplerenone

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Omnicell announces co-marketing partnership agreement for Sentinel RCM application

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence